X4 Pharmaceuticals (XFOR) Operating Income (2017 - 2025)
X4 Pharmaceuticals posted quarterly Operating Income of -$23.7 million for Q4 2025, up 33.64% year-on-year from -$17.7 million in Q4 2024, and up 13.85% on a QoQ basis from -$27.5 million in Q3 2025.
X4 Pharmaceuticals (XFOR) has 9 years of Operating Income data on file, last reported at -$23.7 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income rose 33.64% year-over-year to -$23.7 million; the trailing twelve-month figure through Dec 2025 stood at -$86.9 million (down 138.68% YoY), and the FY2025 full-year result was -$86.9 million, down 138.68% from the prior year.
- Operating Income for Q4 2025 stood at -$23.7 million, up from -$27.5 million in the prior quarter.
- Across five years, Operating Income topped out at $71.1 million in Q2 2024 and bottomed at -$37.3 million in Q1 2024.
- The 5-year median for Operating Income is -$25.4 million (2022), against an average of -$20.2 million.
- The widest annual swing landed in 2024, when Operating Income surged 375.54%; it then plunged 136.89% in 2025.
- A 5-year view of Operating Income shows it stood at -$29.1 million in 2021, then increased by 11.97% to -$25.6 million in 2022, then increased by 1.48% to -$25.2 million in 2023, then plunged by 41.73% to -$35.7 million in 2024, then jumped by 33.64% to -$23.7 million in 2025.
- The last three Operating Income figures came in at -$23.7 million (Q4 2025), -$27.5 million (Q3 2025), and -$26.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | -23.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.70 Mn |
| Sep 30, 2025 | -27.51 Mn |
| Jun 30, 2025 | -26.23 Mn |
| Mar 31, 2025 | -9.44 Mn |
| Dec 31, 2024 | -35.72 Mn |
| Sep 30, 2024 | -34.50 Mn |
| Jun 30, 2024 | 71.10 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | -25.20 Mn |
| Sep 30, 2023 | -27.21 Mn |
| Jun 30, 2023 | -25.81 Mn |
| Mar 31, 2023 | -29.30 Mn |
| Dec 31, 2022 | -25.58 Mn |
| Sep 30, 2022 | -20.15 Mn |
| Jun 30, 2022 | -20.57 Mn |
| Mar 31, 2022 | -21.27 Mn |
| Dec 31, 2021 | -29.06 Mn |
| Sep 30, 2021 | -19.12 Mn |
| Jun 30, 2021 | -19.00 Mn |
| Mar 31, 2021 | -17.94 Mn |
| Dec 31, 2020 | -17.66 Mn |
| Sep 30, 2020 | -16.98 Mn |
| Jun 30, 2020 | -14.66 Mn |
| Mar 31, 2020 | -10.58 Mn |
| Dec 31, 2019 | -10.88 Mn |
| Sep 30, 2019 | -16.98 Mn |
| Jun 30, 2019 | -13.41 Mn |
| Mar 31, 2019 | -10.44 Mn |
| Dec 31, 2018 | -8.05 Mn |
| Sep 30, 2018 | -8.55 Mn |
| Jun 30, 2018 | -6.38 Mn |
| Mar 31, 2018 | -6.11 Mn |
| Dec 31, 2017 | 2.28 Mn |
| Sep 30, 2017 | -13.06 Mn |
| Jun 30, 2017 | -5.64 Mn |
| Mar 31, 2017 | -5.83 Mn |